Grants and Contracts Details
Description
The A4 study is designed to test the hypothesis that solanezumab, will slow decline on a cognitive composite measure designed to be sensitive to early decline in the preclinical stages of AD.
| Status | Finished |
|---|---|
| Effective start/end date | 12/31/12 → 2/29/16 |
Funding
- University of California San Diego Health: $640,800.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.